• twitter
  • twitter


Announcement regarding patents related to Muse cells owned by Tohoku University



Tohoku University, in cooperation with the Life Science Institute Co., Ltd. (a group company of the Mitsubishi Chemical Corporation) and other universities, has filed and acquired a number of patent applications and patents related to Muse cells*.  Now, most of the ownership share of Life Science Institute Co., Ltd. in such patent applications and patents has been transferred to Tohoku University.


While the Muse cell basic patent (Japanese Patent No. 5185443), owned by Professor Mari Dezawa at our university and other inventors, and its related Japanese and foreign patents were exclusively licensed to the Life Science Institute Co., Ltd., the license agreement has been terminated on August 31, 2023, at which time all the rights under the basic patent family has been completely returned to Professor Dezawa and other inventors.


Therefore, most of the patents related to Muse cells are currently concentrated at Tohoku University and now licenses are available even under the basic patent family.


Tohoku University will strive to apply these patents to promote regenerative medicine using Muse cells in collaboration with other universities.


Contact information regarding patents related to Muse cells:

Tohoku University Industry-Academia Collaboration Organization
Intellectual Property Department
TEL: 022-795-5272
e-mail:chizaibu*grp.tohoku.ac.jp (Replace * with @)


*Muse cells(the multilineage-differentiating stress-enduring (Muse) cell.

A new type of pluripotent stem cells discovered from adult human mesenchymal tissue(Kuroda et al., 2010, PNAS;Wakao et al., 2011, PNAS; Kuroda et al., Nature Protocol, 2013), identified as in human dermal fibroblasts that are characterized by stress tolerance, expression of pluripotency markers, self-renewal, and the ability to differentiate from a single cell.  In collaboration with major national and international institutions, we are promoting research on Muse cell-based regenerative medicine for diseases without definitive treatments.